CAJ | 학술논문

　　目的探讨门静脉高压症患者行改良脾-肺固定术后血清肝纤维化指标的变化。方法观察2008年6月至2012年12月郑州大学第一附属医院收治的32例行改良脾-肺固定术患者术前及术后6个月血清Ⅲ型胶原（COL-Ⅲ）、Ⅳ型胶原（COL-Ⅳ）、基质金属蛋白酶1（MMP-1）、基质金属蛋白酶组织抑制因子1（TIMP-1）水平，并做统计学比较分析。结果行改良脾-肺固定术后6个月，血清COL-Ⅲ含量由（20.25±3.20）μg/L降至（16.32±2.35）μg/L，COL-Ⅳ由（112.21±23.90）μg/L降至（57.32±18.74）μg/L；血清MMP-1含量由（16.68±8.56）μg/L升至（26.85±8.95）μg/L，TIMP-1由（227.56±76.84）μg/L降至（132.35±62.42）μg/L，各组数据与术前相比均有统计学意义（P ＜0.01）。结论改良脾-肺固定术可缓解肝脏纤维化进程。
　　목적탐토문정맥고압증환자행개량비-폐고정술후혈청간섬유화지표적변화。방법관찰2008년6월지2012년12월정주대학제일부속의원수치적32례행개량비-폐고정술환자술전급술후6개월혈청Ⅲ형효원（COL-Ⅲ）、Ⅳ형효원（COL-Ⅳ）、기질금속단백매1（MMP-1）、기질금속단백매조직억제인자1（TIMP-1）수평，병주통계학비교분석。결과행개량비-폐고정술후6개월，혈청COL-Ⅲ함량유（20.25±3.20）μg/L강지（16.32±2.35）μg/L，COL-Ⅳ유（112.21±23.90）μg/L강지（57.32±18.74）μg/L；혈청MMP-1함량유（16.68±8.56）μg/L승지（26.85±8.95）μg/L，TIMP-1유（227.56±76.84）μg/L강지（132.35±62.42）μg/L，각조수거여술전상비균유통계학의의（P ＜0.01）。결론개량비-폐고정술가완해간장섬유화진정。
Objective To evaluate the changes of the serum markers for hepatic fibrogenesis in patients of portal hypertension after modified splenopneumopexy treatment. Methods From June 2008 to December 2012, 32 patients with portal hypertension were given modified splenopneumopexy in the First Affiliated Hospital of Zhengzhou University. The levels of COL- Ⅲ , COL- Ⅳ , MMP-1, and TIMP-1 were recorded separately before and 6 months after the operation for a statistical comparison. Results After 6 months, the levels of COL- Ⅲ decreased from (20.25±3.20) μg/L to (16.32±2.35) μg/L, COL- Ⅳdecreased from (112.21±23.90)μg/L to (57.32±18.74)μg/L, the levels of MMP-1 increased from (16.68±8.56) μg/L to (26.85±8.95) μg/L, TIMP-1 decreased from (227.56±76.84) μg/L to (132.35±62.42)μg/L. There were significantly statistical differences between any two groups, P < 0.01. Conclusion The modified splenopneumopexy helps to slow down the degree of liver fibrosis.